新股暗盤 | 昭衍新藥(6127.HK)暗盤段跌5%
格隆匯2月25日丨據輝立證券,昭衍新藥(6127.HK)暗盤段現報143.3港元,較發行價151港元跌5%。公司是一家專注於藥物非臨牀安全性評價的領先合同研究組織,2017年至2019年收益分別為3.01億、4.08億、6.39億元人民幣,溢利分別為7991.7萬、1.05億、1.87億元人民幣,每股有形資產淨值23.82-26.61港元。此次上市全球發售4332.48萬股,其中香港發售1559.7萬股,國際發售2772.78萬股,每手100股,一手中籤率5%,香港公開發售獲310倍認購,淨籌62.861億港元,中國結構調整基金等多家基石投資者已合共認購1375.98萬股,佔完成後公司已發行股本約5.1%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.